Biolab link set to build Nichi-Iko's Thai generic sales
This article was originally published in Scrip
Nichi-Iko Pharmaceutical, one of Japan's largest generics companies, has entered into an alliance with the Thai contract manufacturing group Biolab as part of its strategic Asian expansion plan.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.